Jove
Visualize
Contact Us

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

639
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
639
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

381
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
381
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

274
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
274
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

415
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
415

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Vaccination status of patients undergoing HIV treatment in a hospital in Madrid.

Revista clinica espanola·2026
Same journal

Sulfonylureas and fracture risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Revista clinica espanola·2026
Same journal

Risk factors for the development of in-hospital complications in pluripathological patients.

Revista clinica espanola·2026
Same journal

Features, treatment and 1-year prognosis of patients with heart failure and chronic kidney disease stages 4 or 5.

Revista clinica espanola·2026
Same journal

Notification of suspected adverse drug reactions by nurses to a hospital pharmacovigilance program. Retrospective descriptive study.

Revista clinica espanola·2026
Same journal

Venous thromboembolic disease associated with hormonal contraceptives. Venous Thromboembolism Group of the Spanish Society of Internal Medicine and the Catalan Society of Contraception.

Revista clinica espanola·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 4, 2026

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

992

Iron and heart failure.

M Á de Las Nieves López1

  • 1Instituto de Gestión Sanitaria (INGESA), Área Sanitaria de Melilla, Melilla, España.

Revista Clinica Espanola
|November 11, 2019
PubMed
Summary
This summary is machine-generated.

Intravenous iron may not benefit all heart failure patients. Careful monitoring of iron uptake for hemoglobin synthesis is crucial to optimize outcomes and avoid potential harm in iron therapy.

Keywords:
AnemiaEstrés oxidativoHeart falureHierro oralInsuficiencia cardiacaOral ironOxydative stress

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.3K
Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII
04:48

Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII

Published on: May 4, 2020

8.6K

Related Experiment Videos

Last Updated: Jan 4, 2026

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

992
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.3K
Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII
04:48

Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII

Published on: May 4, 2020

8.6K

Area of Science:

  • Cardiology
  • Hematology
  • Nutritional Science

Background:

  • Iron deficiency is a target for improving heart failure outcomes.
  • Intravenous iron is considered the primary treatment, but its efficacy and safety in heart failure are not fully understood.
  • Hepcidin upregulation in heart failure may limit iron availability and exacerbate oxidative stress.

Purpose of the Study:

  • To evaluate the role of iron in heart failure patients.
  • To determine optimal strategies for iron repletion in heart failure.
  • To identify patient subsets who may not benefit from intravenous iron therapy.

Main Methods:

  • Analysis of laboratory markers for iron deficiency in heart failure.
  • Comparison of outcomes in patients receiving intravenous iron versus placebo.
  • Consideration of iron uptake for hemoglobin synthesis and gradual iron delivery.

Main Results:

  • Some patients receiving intravenous iron showed worse outcomes (admissions, mortality) than placebo.
  • Current laboratory markers for iron deficiency in heart failure are sensitive but lack specificity for identifying non-responders.
  • Oral iron therapy's potential benefits in heart failure patients with anemia and depleted iron stores were not adequately studied in previous trials.

Conclusions:

  • Optimizing hemoglobin levels should be the primary goal of iron therapy in heart failure.
  • Gradual iron administration with monitoring of iron uptake may be a more effective strategy.
  • Standard oral iron therapy should be reconsidered for heart failure patients with anemia and low ferritin levels.